Thymosin Alpha-1 and Sepsis: Why the Larger Trial Matters

Thymosin alpha-1 has been investigated as an adjunct to standard treatment for sepsis. The evidence is particularly useful for understanding how an encouraging early signal can change after a larger trial. Research interest in immune modulation is not the same as demonstrated improvement in survival, and the published findings should be read in that order. [1, 2]

The earlier ETASS study

The 2013 ETASS report described a multicentre, single-blind randomised trial in six Chinese hospitals. It allocated 361 intensive-care patients with severe sepsis to thymosin alpha-1 plus conventional care or a control group. Death from any cause within 28 days was the primary outcome. [1]

Mortality was 26.0% in the thymosin alpha-1 group and 35.0% in the control group. The statistical interpretation was not straightforward: the nonstratified comparison had a P value of 0.062, while the log-rank analysis gave 0.049. The reported relative-risk confidence interval extended from 0.54 to 1.02, including the possibility of no difference. Describing this as unequivocal proof of a survival benefit would overstate the result. [1]

The investigators also observed greater improvement in monocyte HLA-DR, an immune-related marker, at specified follow-up assessments. No serious drug-related adverse event was recorded. These findings justified further investigation, but a biomarker response cannot substitute for confirmation of a patient-important outcome. [1]

What the larger TESTS trial found

TESTS was a double-blind, placebo-controlled phase 3 study conducted across 22 centres in China. It enrolled 1,106 adults with sepsis; 1,089 who received study treatment were included in the modified intention-to-treat analysis. The primary outcome was again 28-day all-cause mortality. [2]

There were 127 deaths among 542 participants in the thymosin alpha-1 analysis group, compared with 132 among 547 placebo participants: 23.4% versus 24.1%. The corrected full text reports a hazard ratio of 0.97, a 95% confidence interval of 0.76–1.24 and P=0.82. The trial did not demonstrate a reduction in its primary mortality outcome. [2, 3]

The publication also reported no statistically significant differences in secondary or safety outcomes. This is not proof that the interventions were identical in every respect, nor does it establish safety in other populations. It means the trial did not demonstrate the proposed benefit using its specified analyses. [2]

Why the correction is worth checking

The journal published a correction in May 2025. Some abstract records retain different numerical estimates from those in the corrected full text. This article uses the corrected primary-outcome figures and links both the study and its correction so readers can trace the version being discussed. [2, 3]

Checking corrections is a practical part of evaluating research. A study identifier is a starting point, not a guarantee that every summary elsewhere reflects the latest version. When a numerical claim matters, the updated article and any linked notices deserve priority over a repeated promotional summary.

A negative trial still leaves useful questions

The larger trial does not erase the biological interest in thymosin alpha-1. It does, however, weaken a broad claim that adding it improves survival in adults with sepsis. A proposed mechanism and an observed immune-marker change need to be connected to clinical outcomes by reliable trials, rather than treated as interchangeable forms of evidence.

The authors discussed limitations, including the possibility that the effect used for sample-size planning was too optimistic and that sepsis is a heterogeneous condition. Such limitations explain what further research might investigate; they do not turn an unsuccessful primary endpoint into a positive finding. [2]

Do not generalise intensive-care research into wellness claims

These studies involved seriously ill hospital patients receiving conventional medical treatment. They cannot establish that thymosin alpha-1 improves everyday immunity in healthy people, prevents common infections, or benefits unrelated conditions. The relevant clinical setting must stay attached to the conclusion.

For a research reader, the key questions are whether allocation was randomised, whether the comparator was appropriate, whether the primary endpoint succeeded, and how much uncertainty remains. Larger and more rigorously controlled evidence should be considered alongside early reports, including when it makes the overall story less favourable.

Bali Peptide Lab is a commercial research-product supplier. This article explains published evidence and is not a treatment recommendation or an administration guide. Research materials are not interchangeable with trial medicines, and suspected sepsis requires urgent medical care rather than self-treatment.